Gr Cheminn Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 11-12-2024
- Paid Up Capital ₹ 2.50 M
as on 11-12-2024
- Company Age 24 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 11-12-2024
- Revenue -26.83%
(FY 2023)
- Profit -74.96%
(FY 2023)
- Ebitda -61.23%
(FY 2023)
- Net Worth -2.77%
(FY 2023)
- Total Assets -2.63%
(FY 2023)
About Gr Cheminn Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.00 Cr.
Zia Ansari and Farah Gokaraju serve as directors at the Company.
- CIN/LLPIN
U24231TG2000PTC035598
- Company No.
035598
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Nov 2000
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Gr Cheminn Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Zia Ansari  | Director | 26-Feb-2021 | Current |
| Farah Gokaraju | Director | 29-Sep-2020 | Current |
Financial Performance of Gr Cheminn Pharma.
Gr Cheminn Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 26.83% decrease. The company also saw a substantial fall in profitability, with a 74.96% decrease in profit. The company's net worth dipped by a decrease of 2.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gr Cheminn Pharma?
Unlock access to Gr Cheminn Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Imperial Projects India Private LimitedActive 18 years 9 months
Zia Ansari and Farah Gokaraju are mutual person
- Gfr Infrastructure Private LimitedActive 18 years 9 months
Zia Ansari and Farah Gokaraju are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 23 May 2006 | ₹2.00 Cr | Open |
How Many Employees Work at Gr Cheminn Pharma?
Unlock and access historical data on people associated with Gr Cheminn Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gr Cheminn Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gr Cheminn Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
